KENILWORTH, N.J., Aug. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced the dissolution of the Consent Decree of Permanent Injunction by the U.S. District Court for the District of New Jersey (Newark). The company recently petitioned the Court to dissolve the decree, which was entered into on May 20, 2002. The decree involved the company’s compliance with current Good Manufacturing Practices (cGMPs) at manufacturing facilities in New Jersey and Puerto Rico.
“This is an important milestone for Schering-Plough as we continue to put issues of the past behind us and make further progress on our Action Agenda,” said Fred Hassan, Schering-Plough chairman and CEO. “Schering-Plough colleagues have worked hard to establish continuous quality improvement and compliance as part of our culture. In turn, we have been working diligently to earn the trust of our stakeholders. Ensuring quality in our products and systems underpins everything we do.”
On Jan. 3, 2006, the company announced it had completed all of the 212 significant steps and 30 validation actions required by Dec. 31, 2005 under the consent decree. The U.S. Food and Drug Administration (FDA) did not oppose the company’s petition.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough’s vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
Schering-Plough Corporation
CONTACT: Media contact, Bernadette Beglin, +1-908-298-4328,+1-908-251-0200 (mobile), or Investor contacts, Alex Kelly or Robyn Brown,+1-908-298-7436, all for Schering-Plough Corporation
Web site: http://www.schering-plough.com/
